Thrombospondin-1 in Differentiated Thyroid Cancer: Dr. Jekyll and Mr. Hyde

REFERENCES

• Robbins J., Merino M. J., Boice J. D., Jr., Ron E., Ain K. B., Alexander H. R., Norton J. A., Reynolds J. Thyroid cancer: a lethal endocrine neoplasm. Ann. Intern. Med. 1991; 115: 133–147
   PubMed Web of Science ®Google Scholar
• Woolner L. B., Beahrs O. H., Black B. M., Mc C. W., Keating F. R., Jr. Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am. J. Surg. 1961; 102: 354–387
   PubMed Web of Science ®Google Scholar
• DeGroot L. J., Kaplan E. L., Shukla M. S., Salti G., Straus F. H. Morbidity and mortality in follicular thyroid cancer. J. Clin. Endocrinol. Metab. 1995; 80: 2946–2953
   PubMed Web of Science ®Google Scholar
• Caron N. R., Clark O. H. Papillary thyroid cancer: surgical management of lymph node metastases. Curr. Treat. Options Oncol. 2005; 6: 311–322
   PubMedGoogle Scholar
• Bergholm U., Adami H. O., Bergstrom R., Johansson H., Lundell G., Telenius-Berg M., Akerstrom G. Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer 1989; 63: 1196–1204
   PubMed Web of Science ®Google Scholar
• Nel C. J., van Heerden J. A., Goellner J. R., Gharib H., McConahey W. M., Taylor W. F., Grant C. S. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin. Proc. 1985; 60: 51–58
   PubMed Web of Science ®Google Scholar
• Kebebew E., Greenspan F. S., Clark O. H., Woeber K. A., McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005; 103: 1330–1335
   PubMed Web of Science ®Google Scholar
• McIver B., Hay I. D., Giuffrida D. F., Dvorak C. E., Grant C. S., Thompson G. B., van Heerden J. A., Goellner J. R. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130: 1028–1034
   PubMed Web of Science ®Google Scholar
• Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell. Biol. 1995; 130: 503–506
   PubMed Web of Science ®Google Scholar
• Baenziger N. L., Brodie G. N., Majerus P. W. A thrombin-sensitive protein of human platelet membranes. Proc. Natl. Acad. Sci. USA 1971; 68: 240–243
   PubMed Web of Science ®Google Scholar
• Mosher D. F., Doyle M. J., Jaffe E. A. Synthesis and secretion of thrombospondin by cultured human endothelial cells. J. Cell. Biol. 1982; 93: 343–348
   PubMed Web of Science ®Google Scholar
• Jaffe E. A., Ruggiero J. T., Leung L. K., Doyle M. J., McKeown-Longo P. J., Mosher D. F. Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc. Natl. Acad. Sci. USA 1983; 80: 998–1002
   PubMed Web of Science ®Google Scholar
• Raugi G. J., Mumby S. M., Abbott-Brown D., Bornstein P. Thrombospondin: synthesis and secretion by cells in culture. J. Cell. Biol. 1982; 95: 351–354
   PubMed Web of Science ®Google Scholar
• Bornstein P., Sage E. H. Thrombospondins. Methods Enzymol. 1994; 245: 62–85
   PubMed Web of Science ®Google Scholar
• Roberts D. D. Regulation of tumor growth and metastasis by thrombospondin-1. Faseb J. 1996; 10: 1183–1191
   PubMed Web of Science ®Google Scholar
• Adams J. C. Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 2001; 17: 25–51
   PubMedGoogle Scholar
• Sargiannidou I., Zhou J., Tuszynski G. P. The role of thrombospondin-1 in tumor progression. Exp. Biol. Med. (Maywood) 2001; 226: 726–733
   PubMed Web of Science ®Google Scholar
• Good D. J., Polverini P. J., Rastinejad F., Le Beau M. M., Lemons R. S., Frazier W. A., Bouck N. P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 1990; 87: 6624–6628
   PubMed Web of Science ®Google Scholar
• Iruela-Arispe M. L., Bornstein P., Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc. Natl. Acad. Sci. USA 1991; 88: 5026–5030
   PubMed Web of Science ®Google Scholar
• Tuszynski G. P., Gasic T. B., Rothman V. L., Knudsen K. A., Gasic G. J. Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res. 1987; 47: 4130–4133
   PubMed Web of Science ®Google Scholar
• Castle V. P., Dixit V. M., Polverini P. J. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells. Lab. Invest. 1997; 77: 51–61
   PubMed Web of Science ®Google Scholar
• Bunone G., Vigneri P., Mariani L., Buto S., Collini P., Pilotti S., Pierotti M. A., Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 1999; 155: 1967–1976
   PubMed Web of Science ®Google Scholar
• Scarpino S., Di Napoli A., Taraboletti G., Cancrini A., Ruco L. P. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells. J. Pathol. 2005; 205: 50–56
   PubMed Web of Science ®Google Scholar
• Patey M., Delemer B., Bellon G., Martiny L., Pluot M., Haye B. Immunohistochemical study of thrombospondin and its receptors alpha root of beta 3 and CD36 in normal thyroid and in thyroid tumours. J. Clin. Pathol. 1999; 52: 895–900
   PubMed Web of Science ®Google Scholar
• Tanaka K., Sonoo H., Kurebayashi J., Nomura T., Ohkubo S., Yamamoto Y., Yamamoto S. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clin. Cancer Res. 2002; 8: 1125–1131
   PubMed Web of Science ®Google Scholar
• Kim D. S., Franklyn J. A., Stratford A. L., Boelaert K., Watkinson J. C., Eggo M. C., McCabe C. J. Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer. J. Clin. Endocrinol. Metab. 2006; 91: 1119–1128
   PubMed Web of Science ®Google Scholar
• Soula-Rothhut M., Coissard C., Sartelet H., Boudot C., Bellon G., Martiny L., Rothhut B. The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp. Cell Res. 2005; 304: 187–201
   PubMed Web of Science ®Google Scholar
• Ghoneim C., Soula-Rothhut M., Blanchevoye C., Martiny L., Antonicelli F., Rothhut B. Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J. Biol. Chem. 2007; 282: 15490–15497
   PubMed Web of Science ®Google Scholar
• Rath G. M., Schneider C., Dedieu S., Rothhut B., Soula-Rothhut M., Ghoneim C., Sid B., Morjani H., El Btaouri H., Martiny L. The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim. Biophys. Acta 2006; 1763: 1125–1134
   PubMed Web of Science ®Google Scholar